Your session is about to expire
← Back to Search
Physical activity for Sleep Apnea (RAP Trial)
N/A
Waitlist Available
Led By Jean-Louis Pépin, Pr MD PhD
Research Sponsored by AGIR à Dom
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up to baseline at 12 weeks
Awards & highlights
RAP Trial Summary
Investigators hypothesize that CPAP treatment for suppressing OSAS in combination with a physical activity program will optimize 24-hour blood pressure control in patients with OSA-related resistant hypertension.
Eligible Conditions
- Sleep Apnea
- Hypertension
RAP Trial Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ to baseline at 12 weeks
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~to baseline at 12 weeks
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Systolic arterial blood pressure assessed by 24-hours home blood pressure monitoring
Secondary outcome measures
Change in physical activity : Metabolic Equivalents (METS)
Change in physical activity : Number of steps per day
Change in physical activity: number of hour per day of physical activity
+4 moreRAP Trial Design
2Treatment groups
Experimental Treatment
Active Control
Group I: Physical activityExperimental Treatment1 Intervention
Obstructive sleep apnea and resistant hypertension controlled + physical activity
Group II: Control GroupActive Control1 Intervention
Obstructive sleep apnea and resistant hypertension controlled
Find a Location
Who is running the clinical trial?
University Hospital, GrenobleOTHER
794 Previous Clinical Trials
250,017 Total Patients Enrolled
12 Trials studying Sleep Apnea
2,693 Patients Enrolled for Sleep Apnea
AGIR à DomLead Sponsor
34 Previous Clinical Trials
5,000 Total Patients Enrolled
4 Trials studying Sleep Apnea
245 Patients Enrolled for Sleep Apnea
Jean-Louis Pépin, Pr MD PhDPrincipal InvestigatorLaboratoire EFCR, CHU de Grenoble, 38043, Grenoble, France
1 Previous Clinical Trials
50 Total Patients Enrolled
Frequently Asked Questions
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Share this study with friends
Copy Link
Messenger